Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHACYLOB: Methylphenidate PK in Obese vs Non-Obese ADHD Adults
NCT07121621Phase 4Not yet recruiting
- Sponsor
- University Hospital Tours
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by University Hospital Tours. Primary endpoint: Area under the curve (AUC) of blood concentrations of methylphenidate (MPH) and ritalinic acid (APP) at 8 hours. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07121621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07121621.